The Smart Choice: Closed System Drug-Transfer Devices for Safety and Savings

Hazardous drugs are prepared and administered daily in hospital pharmacies, oncology units, outpatient infusion centers and veterinary clinics. While these medications are essential for treatment, they also present an occupational risk for healthcare professionals during compounding, reconstitution, transfer and administration. Exposure to hazardous drugs can occur even during routine, correctly performed workflows.

Acute exposure has been associated with skin and mucous membrane irritation, respiratory symptoms, and neurological effects, while chronic low-level exposure is linked to reproductive toxicity, genetic damage, and increased cancer risk among healthcare workers. These risks extend beyond pharmacists, nurses and veterinarians to environmental services staff, waste handlers, and others working in contaminated care areas.

Closed-System Drug-Transfer Devices (CSTDs) were developed specifically to reduce these risks. They minimize occupational exposure to hazardous drugs while also improving medicine utilization and workflow efficiency. As a result, CSTDs address safety as well as financial performance. Their adoption represents both a significant clinical safety measure and a meaningful operational investment.

A Closed System Drug-Transfer Device is defined by the US National Institute for Occupational Safety and Health (NIOSH) as a drug-transfer device that mechanically prevents the transfer of environmental contaminants into the system and the escape of hazardous drugs or vapor concentrations outside the system. Unlike traditional or partially closed systems, a true CSTD provides continuous containment throughout drug preparation and administration - hazardous drugs vapors and liquids are prevented from escaping the closed system. At the same time, environmental contaminants are prevented from entering the fluid path ensuring drug sterility.

CSTDs are used at key transfer points in the medication-use process, including vial access, syringe filling, transfer to IV bags and final connection to administration sets.

Many CSTDs incorporate mechanical membranes. In designs like Simplivia’s Chemfort®, a drug-binding matrix mechanical barrier physically locks in hazardous molecules while locking out contaminants. This innovative and intuitive design reduces the risk of exposure when handling medications including antineoplastics, cytotoxics, antiviral agents and other drugs classified as hazardous under NIOSH criteria.

In traditional handling, exposure occurs in various ways, including aerosol formation during vial access, liquid leakage during transfer, vapor escape and accumulation of surface contamination. In addition, contamination persists on gloves, counters, isolators and infusion equipment, creating an ongoing exposure risk well beyond the moment of preparation.

CSTDs interrupt these pathways by ensuring a mechanically closed system during drug transfer. Multiple environmental monitoring studies have shown that properly implemented CSTDs significantly reduce detectable surface contamination and airborne hazardous drug presence in both pharmacy cleanrooms and clinical care areas.

Open systems such as standard needle-and-syringe setups or vial spikes rely on partial physical barriers for containment. Biological safety cabinets and isolators provide environmental protection, but do not eliminate exposure at the point of drug transfer. These controls reduce dispersion, but cannot fully prevent vapor escape or droplet formation during manipulation of hazardous drugs inside the cabinet.

CSTDs add a true engineering control throughout the transfer process itself. This distinction is reflected in regulatory guidance globally. From a risk-control perspective, open systems rely on administrative and behavioral controls, while CSTDs introduce mechanical containment that functions independently of individual technique.

Antineoplastic and specialty hazardous drugs, especially oncology medications, represent a significant portion of hospital pharmacy expenditure. Drug waste occurs routinely through residual volumes left in single-dose vials, discarded partial vials, and shortened beyond-use dating due to contamination risk. Even small inefficiencies in handling translate into substantial financial losses when applied across high-cost drug portfolios.

By maintaining a closed sterile pathway, CSTDs support scientifically validated sterile compounding practices that can enable extended beyond-use dating. This allows partial vials to be used more efficiently and reduces early disposal of high-value medications, resulting in more life-saving treatment for patients from the same drug inventory. At the same time, easy-to-use CSTD systems like Simplivia’s Chemfort®, where just four SKUs can cover up to 90% of all preparations, streamline procurement, reduce stocking complexity and minimize line-item waste across pharmacy operations.

From an operational standpoint, facilities implementing CSTDs often see reductions in overall drug purchasing volume, fewer emergency procurements driven by unexpected wastage, and improved predictability in inventory planning. These efficiencies translate directly into a lower cost per treated patient and higher efficiency per prepared dose, strengthening both budget control and long-term return on pharmaceutical investment.

The indirect financial burden of hazardous drug exposure includes increased sick leave, and the use of overtime or temporary staffing to maintain service continuity. These labor-related costs are often underreported, but accumulate steadily over time.

Exposure to hazardous drugs has regulatory and legal significance which also carries substantial financial risk. Occupational exposure complaints, workers’ compensation claims and citations related to hazardous drug handling can result in penalties, mandated remediation, and reputational damage. In turn, this can negatively impact staff retention and recruitment.

From a health economics and ROI perspective, prevention is cheaper than response. Preventive investment in engineering controls like CSTDs consistently outperforms reactive spending. CSTDs provide predictable, sustained risk reduction that is not dependent on flawless human behavior, delivering long-term financial protection in parallel with clinical safety.

While Closed System Drug-Transfer Devices provide robust mechanical protection, their effectiveness depends on standardized implementation and proper user technique. Healthcare staff training must address correct connection and disconnection procedures, pressure equalization management, and appropriate response to device integrity issues.

Facility workflows must be updated to fully integrate CSTDs into compounding, administration, and disposal processes. When these devices are incorporated into validated aseptic technique and hazardous-drug handling protocols, safety becomes an embedded part of routine practice rather than left to chance.

Procurement decisions should account for device compatibility with existing infusion pumps and administration lines, availability of vial adaptors and connectors across drug formats, and the learning curve for pharmacy, nursing and veterinary staff. Regular audits and refresher training also ensure ongoing protection and adherence to regulatory requirements.

Selecting a CSTD should follow a clear, practical decision process rather than a purely technical or unit-price comparison. Key factors include the types of drugs handled, the volume and frequency of preparation, the level of staff exposure risk, the regulatory environment and overall budget constraints. High-priority environments for full CSTD implementation include oncology compounding pharmacies, hospital infusion centers, specialty drug clinics and veterinary clinics. In these locations, staff are repeatedly exposed to high-risk agents and drug purchase costs are significant.

From a financial perspective, administrators must balance upfront device cost against long-term savings from improved safety, reduced waste and lower regulatory risk.

While simpler systems may appear less expensive on a per-unit basis, this approach often underestimates the true cost of exposure incidents, drug loss, compliance failures and staff turnover. For this reason, CSTD purchasing decisions should be based on a total-cost-of-ownership model, which provides a more accurate picture of long-term economic and operational value.

Closed-System Transfer Devices play a central role in modern hazardous drug handling by addressing both safety and cost at the same time. They protect healthcare workers from exposure, preserve the sterility and integrity of high-value medications, reduce preventable drug waste and limit institutional liability linked to contamination and regulatory non-compliance.

For pharmacists, oncology nurses and veterinarians, CSTDs support daily workforce safety and workflow consistency. For hospital and clinic leadership, they align directly with financial stewardship, helping control drug loss, manage risk and support long-term sustainability. In this sense, CSTDs serve three critical priorities at once: patient safety, staff protection, and responsible resource management.

CSTDs should not be viewed merely as a compliance checkbox. They are a strategic investment in safer, more efficient healthcare delivery. Institutions are encouraged to evaluate their current drug-handling workflows, quantify exposure risk and medication waste and assess how CSTDs can strengthen their long-term hazardous drug safety strategy.

Chemfort® is built to meet these demands with a brilliantly simple and intuitive product family that integrates directly into pharmacy, nursing and clinic workflows. Chemfort® supports efficient training and inventory management, while its validated containment performance helps institutions strengthen both regulatory compliance and clinical quality.

By adopting Chemfort®, healthcare teams gain a vial-to-vein platform that enhances safety at every touchpoint - during preparation, transport, and administration - without slowing productivity or increasing operational complexity.

To learn more or schedule a demonstration, contact our team.

A Closed System Drug-Transfer Device is an engineered control that prevents hazardous drug vapors and liquids from escaping the drug pathway during preparation and administration. CSTDs maintain a sealed, pressure-managed fluid pathway to protect staff. Simultaneously, CSTDs prevent contaminants from entering the drug pathway, preserving drug sterility.

CSTDs reduce occupational exposure to hazardous drugs, lower surface contamination in cleanrooms and infusion areas, and help prevent aerosol formation and micro-leaks during vial access and transfer. This improves staff safety and supports compliance with NIOSH, USP <800> and institutional safety protocols.

Yes. By maintaining a closed sterile pathway, CSTDs support practices that can extend beyond-use dating and minimize the disposal of partially used vials. This reduces overall drug purchasing volume, lowers emergency procurement needs and improves cost efficiency for high-value oncology and specialty medications.

Facilities should adopt CSTDs when handling hazardous drugs regularly - especially in oncology pharmacies, infusion centers, hospital cleanrooms, and veterinary clinics. They are recommended whenever staff exposure risk, drug cost, regulatory requirements, or workflow safety justify an engineering control instead of relying solely on open systems or user-dependent technique.